2017-04-07 16:03:12 UTC

Hand-Picked Gastrointestional Oncology Sessions at DDW® 2017

April 10, 2017

Rhonda Souza, MD, AGAF, (chair) and John P. Lynch, MD, PhD, (vice chair) reveal their section's most anticipated DDW sessions.

Check out must-see sessions for the Gastrointestional Oncology section at Digestive Disease Week (DDW) 2017. This section, led by Rhonda Souza, MD, AGAF, (chair) and John P. Lynch, MD, PhD, (vice chair), provides educational leadership in topics central to the initiation, progression, diagnosis and treatment of gastrointestinal tract cancers via high quality programming in clinical, translational and basic science research.

Additional council programming can be found in the AGA Institute Council Highlights at DDW 2017 booklet. Once available, the DDW Mobile App will have the most up-to-date information to plan your itinerary (launching in early April).

Session Title: Gastrointestinal Oncology Distinguished Abstract Plenary and Section Business Meeting 
Session Date: Monday, May 8, 2017
Session Time: 4 p.m.
Why You Should Attend: This session will present the latest advances in GI oncology clinical and basic science research. If you are interested in supporting the section’s mission, invigorating their outreach, or have ideas for 2018 DDW symposia topics, then don’t miss the GI oncology section business meeting immediately following the plenary session.

Session Title: GRG Spring Symposium: Engineered T Cells and Immune-Checkpoint Therapies for GI Cancers
Session Date: Sunday, May 7, 2017
Session Time 2 p.m.
Why You Should Attend: Immune checkpoint and chimeric antigen receptor T-cell therapies represent exciting advances cancer immunotherapy. Two leaders in the field, Carl June, MD, and Luis Diaz, MD, will discuss the current efforts to utilize these innovative approaches in the treatment of GI cancers. Attendees will gain an understanding of novel T cell engineering approaches and immune checkpoint therapies and their potential application to GI cancers. They will also develop a broader understanding of the role of immune responses in cancer progression and immune-based therapies.

Session Title: Using CRISPR/Cas9 to Develop Novel Models for GI Cancer
Session Date: Sunday, May 7, 2017
Session Time: 8 a.m.
Why You Should Attend: The genome editing technology known as CRISPR/Cas9 holds tremendous potential as a tool for GI cancer investigators, from improving the modeling of cancer pathogenesis to innovative therapeutics. This session will broadly cover this subject, from the basic mechanics of CRISPR genome editing, its utilization to engineer oncogenic chromosomal rearrangements and oncogene/tumor-suppressor mutations in human organoid cultures, and in vivo editing approaches that have utility in both modeling and treating GI cancers.

More on Cancer of the Gallbladder and Bile Ducts

Headlines from the 2018 Gastrointestinal Cancers Symposium

Jan. 24, 2018

Novel approaches for CRC screening, new treatment options for GI cancers, and more presented at the meeting, which is co-sponsored by AGA.

Digestive Disease Week® (DDW)

Dec. 19, 2017

Digestive Disease Week® (DDW) is the premier meeting for the GI professional. Every year it attracts approximately 15,000 physicians, researchers and academics from around the world who desire to stay up-to-date in the field.

Trending in AGA Community: Hard Cancer Questions

Aug. 3, 2016

AGA Community reached 1,000 discussion posts over the weekend. Trending this week in the forum is the topic of cancer risk and prevention.